Illumina snares sequencing tech in $60M buyout

Illumina has struck a $60 million deal to enhance its genetic sequencing technology with the acquisition of Avantome. Avantome's owners will get $25 million of that upfront with the rest coming in contingency payments. And company founders Mostafa Ronaghi and Helmy Eltoukhy say they will take a place in Illumina's management team.

- read the AP story

Suggested Articles

Across its 15-year history, Omega Funds has a hand in a clutch of high-profile biotechs such as Editas Medicine and Juno Therapeutics.

After Novartis’ near $10 billion buyout of The Medicines Company, many thought cardiovascular therapies were hot again.

The data position Leo to file for approval of the Dupixent rival in atopic dermatitis next year.